Amgen (AMGN) News Today

Amgen Inc. (NASDAQ: AMGN) shares dipped today despite mostly positive headlines. Investors weighed an analyst price-target hike, a key FDA approval boost for Repatha®, and ongoing royalty deals linked to Amgen’s Imdelltra lung-cancer therapy.

• Positive Sentiment: Piper Sandler raised its target for AMGN from $328 to $342 and maintained an “overweight” rating, implying roughly 18.6% upside from current levels. Article Title Article Title
• Positive Sentiment: The FDA broadened Repatha® (evolocumab) approval to include adults at increased risk for major adverse cardiovascular events due to uncontrolled LDL-C, potentially driving higher sales of Amgen’s top cholesterol therapy. Article Title
• Neutral Sentiment: Royalty Pharma agreed to acquire up to $950 million of royalty interests in Amgen’s Imdelltra lung-cancer drug from BeOne Medicines, highlighting Imdelltra’s market value though Amgen itself isn’t directly selling royalties. Article Title
• Neutral Sentiment: AstraZeneca and Amgen provided an update on their Phase 3 lung cancer clinical trial collaboration, which, if successful, could expand Amgen’s oncology pipeline. Article Title